#Paris #France #Theranostics #DOSIsoft #Radiopharmaceutical

DOSIsoft Theranostics: A New Era in Personalized Nuclear Medicine

In a noteworthy development in the field of nuclear medicine, DOSIsoft, a renowned provider of dosimetry software for radiation oncology and nuclear medicine, has announced the establishment of a new division—DOSIsoft Theranostics. This new unit is set to drive advances in software innovations for theranostics, focusing on personalized approaches to diagnostic and therapeutic strategies within clinical settings.

Scheduled to debut ahead of the upcoming SNMMI (Society of Nuclear Medicine and Molecular Imaging) 2026, DOSIsoft Theranostics aims to foster a more extensive application of theranostic software in routine clinical practice. By taking this step, DOSIsoft is positioning itself as a neutral, trustworthy partner in the broader clinical and industrial ecosystem, dedicated to accelerating innovation and facilitating collaborations in theranostics.

The growing emphasis on integrating diagnostics with targeted therapies marks a significant shift towards personalized treatment options in patient care. With over two decades of experience, DOSIsoft aims to leverage its expertise to enhance the development of innovative software solutions designed for radiopharmaceutical therapies. The goal is to improve quantitative imaging, cultivate AI-driven workflows, and advance personalized patient care.

Embracing Advanced Software Tools

DOSIsoft Theranostics is particularly focused on refining how patient therapy monitoring is managed, recognizing that this increasingly requires multiple imaging modalities and coordinating various treatment cycles, along with combined therapeutic approaches. To this end, the unit will implement state-of-the-art software tools, alongside specialized scientific knowledge, to drive both research and clinical innovation.

At the core of DOSIsoft Theranostics is PLANET®, the company’s flagship software platform for theranostics. This platform has evolved from DOSIsoft’s extensive experience in treatment planning for external beam radiation therapy, now offering advanced voxel-based dosimetry functionalities compatible with various radionuclides, as well as full multimodal DICOM interoperability. PLANET® is proudly FDA-cleared via the 510(k) pathway, carries CE marking, and is currently in use at leading hospitals and academic centers around the globe. The vendor-neutral architecture of the platform grants clinical teams the flexibility to support varying workflows and therapeutic strategies, enhancing its relevance in diverse clinical environments.

Marc Uszynski, the CEO of DOSIsoft, commented on the launch, stating, “The formation of this independent theranostics organization reflects DOSIsoft’s long-term commitment to this rapidly growing area. DOSIsoft Theranostics now has the strategic focus and agility needed to expedite innovations, forge new partnerships, and expand theranostic applications worldwide.”

As the sector of theranostics progresses, the contributions from DOSIsoft Theranostics will be pivotal in addressing the growing demand for personalized medicine in cancer therapy. This innovative pathway represents a significant leap toward enhancing quality and safety in cancer treatment processes.

A Legacy of Excellence

Founded in 2002, DOSIsoft has established itself as a leader in dosimetry software, with more than 1,000 installations across over 800 clinical centers in 80 countries. The company's mission has always been to improve the quality of cancer treatments and enhance patient safety. As a spin-off from respected institutions such as Gustave Roussy and Institut Curie, DOSIsoft continues to champion innovation in partnership with leading cancer treatment centers worldwide. Notably, DOSIsoft is also a participant in the European project Thera4Care (Theranostics Ecosystem for Personalized Care), showcasing their dedication to advancing therapeutic innovations.

DOSIsoft Theranostics will be present at SNMMI 2026 (#1358), where attendees can explore the future possibilities of theranostic solutions in nuclear medicine.